Diazoxide choline CR is under clinical development by Soleno Therapeutics and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Diazoxide choline CR’s likelihood of approval (LoA) and phase transition for Prader-Willi Syndrome (PWS) took place on 01 Dec 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Diazoxide choline CR Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Diazoxide choline CR overview

Diazoxide choline controlled release (DCCR) is under development for the treatment of Prader-Willi syndrome, hypothalamic and SH2B1 deficiency obesity, hyperphagic obesity and Smith-Magenis syndrome. The drug candidate is formulated as a tablet and administered through oral route. It targets ATP sensitive inward rectifier potassium channel 11. It is a new chemical entity (NCE). The drug candidate was also under development for the treatment of hypertriglyceridemia and dyslipidemia.

Soleno Therapeutics overview

Soleno Therapeutics (Soleno) formerly Capnia Inc, is a medical equipment company that designs, develops and commercializes novel therapeutic and diagnostic products. The company provides products such as serenz, cosense, and others. It offers serenz that is a hand-held device, which is used to obtain relief from the symptoms of allergies. Soleno provides cosense which is a portable device that is used to measure carbon monoxide in exhaled breath. The company offers various solutions to properly diagnose, monitor and care for children. It markets its products through its network of distributors. Soleno is headquartered in Redwood, California, the US.

Quick View Diazoxide choline CR LOA Data

Report Segments
  • Innovator
Drug Name
  • Diazoxide choline CR
Administration Pathway
  • Oral
Therapeutic Areas
  • Genetic Disorders
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.